Ansa Biotechnologies, Inc., a leader in next-generation DNA synthesis, has appointed Jason T. Gammack as its new chief executive officer as the company advances its early access program for complex synthetic genes and gene fragments, gearing up for a full commercial service launch. Founder and former CEO Dan Lin-Arlow, PhD, will transition to the role of chief scientific officer while continuing to contribute to the company's growth.

Ansa's innovative DNA synthesis platform relies on precise enzymatic reagents to enable rapid and controlled single-base additions to DNA molecules. This eco-friendly method eliminates the use of harsh chemicals and preserves the integrity of the growing DNA molecule, allowing for the direct and accurate synthesis of sequences that can be hundreds or even thousands of bases long. This breakthrough technology simplifies the construction of longer sequences and facilitates the synthesis of complex sequences that were previously challenging to produce with traditional methods.

Ansa's approach promises to accelerate innovation across various industries reliant on synthetic DNA, including biologic therapeutics such as antibodies, gene therapies, and cell therapies, as well as the biomanufacturing of chemicals, materials, foods, and biofuels.

“Ansa Biotechnologies has reached an inflection point in our ongoing mission to shape the future of biology,” said Dr. Lin-Arlow. “We are thrilled to welcome Jason to our team at this pivotal time for our business. His visionary leadership and extensive expertise commercializing life sciences tools and services will be instrumental as we launch our first service offering, drive operational excellence, and position the company for long-term success.”

With over 30 years of experience in the life sciences industry, Gammack brings a wealth of knowledge to Ansa Biotechnologies. His previous roles include co-founder and CEO of Resolve Biosciences, where he spearheaded the launch of a groundbreaking multi-analyte, highly multiplex spatial analysis technology. Gammack also served as chief commercial officer at Inscripta and held leadership positions at QIAGEN, Ingenuity Systems, Sigma-Aldrich, and other prominent companies.

“Ansa’s novel and powerful DNA synthesis approach will soon redefine the DNA synthesis landscape and open the door to new sustainable solutions across a wide variety of industries,” said Gammack. “I’m looking forward to working with Dan and our talented team of employees, investors, and collaborators as we empower more researchers with the ability to unlock the next wave of scientific breakthroughs.”

Through Ansa’s early access program, scientists can explore areas previously limited due to the difficulty of synthesizing DNA sequences. To learn more about the program, visit https://ansabio.com/early-access/

‍